# Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001

> **NCT05508594** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cessatech A/S** · enrollment: 220 (actual)

## Conditions studied

- Pain

## Interventions

- **DRUG:** CT001
- **DRUG:** Placebo
- **DRUG:** Sufentanil
- **DRUG:** Ketamine

## Key facts

- **NCT ID:** NCT05508594
- **Lead sponsor:** Cessatech A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-05
- **Primary completion:** 2023-10-05
- **Final completion:** 2023-10-05
- **Target enrollment:** 220 (ACTUAL)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05508594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05508594, "Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05508594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*